Helix Acquisition Corp. (HLXA)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Helix Acquisition Corp. (HLXA) with AI Score 47/100 (Grade C). Helix Acquisition Corp. Sector: Healthcare.
Last analyzed: Mar 18, 2026HLXA: the 1 perspectives are evenly split.
How is this calculated? →Helix Acquisition Corp. (HLXA) Healthcare & Pipeline Overview
Helix Acquisition Corp. II is a special purpose acquisition company (SPAC) targeting the biotechnology sector. It seeks to merge with a promising biotech company, providing access to public markets. The company's management team brings experience in healthcare investing and operations, potentially offering a competitive advantage in deal sourcing and execution.
What Is the Investment Thesis for HLXA?
An investment in Helix Acquisition Corp. II is speculative and contingent on the company's ability to successfully identify and merge with a viable biotechnology company. The potential upside lies in the target company's future performance and market valuation. However, the investment carries significant risk, as the value of HLXA shares is heavily dependent on the quality of the acquisition target and the terms of the merger agreement. Investors should carefully consider the risks and uncertainties associated with SPAC investments before investing in HLXA.
Based on FMP financials and quantitative analysis
Who Are HLXA's Competitors?
HLXA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| ABVX Abivax S.A. | $143.99 | -0.46% | 10B | 76 |
| NWPHF Newron Pharmaceuticals S.p.A. | $20.00 | +0.00% | $416.12M | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| MIRM Mirum Pharmaceuticals, Inc. | $121.91 | -2.93% | $6.12B | 68 |
| BCYC Bicycle Therapeutics plc | $4.37 | +0.54% | $303.50M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HLXA's Key Strengths?
- Experienced management team.
- Focus on the high-growth biotechnology sector.
- Access to capital through the SPAC structure.
What Are HLXA's Weaknesses?
- Dependence on identifying and merging with a suitable target company.
- Competition from other SPACs.
- Uncertainty regarding the future performance of the acquired company.
What Are the Key Risks for HLXA?
- Financial-distress signal — its Altman Z-Score of 1.31 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-85.7%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
What Opportunities Does HLXA Have?
- Acquire a high-growth potential biotechnology company.
- Benefit from the increasing demand for innovative healthcare solutions.
- Create value for shareholders through successful execution of the business combination.
What Threats Does HLXA Face?
- Inability to find a suitable target company.
- Failure to complete the business combination.
- Poor performance of the acquired company.
- Changes in the regulatory environment.
What Are HLXA's Competitive Advantages?
- Experienced management team with expertise in healthcare investing and operations.
- Access to capital through the SPAC structure.
- Network of relationships in the biotechnology industry.
What Does HLXA Do?
Helix Acquisition Corp. II is a blank check company, also known as a special purpose acquisition company (SPAC). It was formed with the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. While the company may pursue an acquisition opportunity in any industry or geographic location, it intends to focus on businesses in the biotechnology sector. SPACs like Helix Acquisition Corp. II offer private companies a faster and potentially less expensive route to becoming publicly traded compared to a traditional initial public offering (IPO). The company's success depends on its ability to identify and merge with a high-growth potential biotechnology company, creating value for its shareholders. Helix Acquisition Corp. II is actively searching for suitable target companies and conducting due diligence to evaluate potential merger candidates. The ultimate goal is to bring a promising biotech company to the public markets, enabling it to access capital for further research, development, and commercialization of its products or technologies.
What Products and Services Does HLXA Offer?
- A special purpose acquisition company (SPAC).
- Formed to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses.
- Intends to focus on businesses in the biotechnology sector.
- Offers private companies a faster route to becoming publicly traded compared to a traditional IPO.
- Actively searching for suitable target companies and conducting due diligence.
- Aims to bring a promising biotech company to the public markets.
How Does HLXA Make Money?
- Raise capital through an initial public offering (IPO).
- Seek a merger target in the biotechnology sector.
- Complete a business combination (merger, acquisition, etc.).
- Generate returns for shareholders through the growth of the acquired company.
What Industry Does HLXA Operate In?
The biotechnology industry is characterized by high growth potential and significant investment activity. SPACs have become an increasingly popular mechanism for biotech companies to access public markets, offering a faster and more flexible alternative to traditional IPOs. However, the SPAC market is also highly competitive, with numerous SPACs vying for attractive acquisition targets. The success of Helix Acquisition Corp. II will depend on its ability to differentiate itself from other SPACs and secure a compelling merger opportunity in the biotechnology sector.
Who Are HLXA's Key Customers?
- Shareholders who invest in the SPAC.
- The private biotechnology company that merges with the SPAC.
F-Score 1/9Financial Health
Helix Acquisition Corp.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 1.31 places it in the distress zone, a signal of elevated financial risk.
ROE -86%Key Financial Metrics
Return on equity for Helix Acquisition Corp. stands at -85.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -64.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -43.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 8.60 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -27.2%, the inverse of the P/E and a quick read on earnings relative to price.
Helix Acquisition Corp. (HLXA) Valuation Context
Relative to its peer group, HLXA's quantitative score of 47/100 is below the peer average of 76/100.
Net sellingInsider Activity
The most recent 6 insider filings for Helix Acquisition Corp. break down as 5 sales and 1 purchases. On net that is roughly 2.5M shares disposed (about $4.3M), a signal worth weighing alongside the fundamentals.
HLXA Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Experienced management team.
- Focus on the high-growth biotechnology sector.
- Access to capital through the SPAC structure.
Bear Case
- Dependence on identifying and merging with a suitable target company.
- Competition from other SPACs.
- Uncertainty regarding the future performance of the acquired company.
- Inability to find a suitable target company.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
HLXA Latest News
No recent news available for HLXA.
HLXA Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HLXA.
Price Targets
Wall Street price target analysis for HLXA.
HLXA MoonshotScore
What does this score mean?
The MoonshotScore rates HLXA's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Helix Acquisition Corp. Healthcare Stock: Key Questions Answered
What does HLXA do?
Helix Acquisition Corp. II is a special purpose acquisition company (SPAC) focused on merging with a private biotechnology company. It raises capital through an initial public offering with the sole purpose of finding and acquiring a promising business. Once a target is identified, HLXA shareholders vote on whether to approve the merger. If approved, the private company becomes publicly traded under a new ticker symbol, and HLXA shareholders become shareholders of the new entity. The success of HLXA depends entirely on the quality and future performance of the acquired company.
What do analysts say about HLXA stock?
As a SPAC, HLXA's stock performance is primarily driven by speculation surrounding potential merger targets and the overall market sentiment towards SPACs. Analyst ratings are typically initiated after a merger target is announced, focusing on the target company's fundamentals, growth prospects, and valuation. Prior to a merger announcement, analyst coverage may be limited, with assessments largely based on the management team's experience and the attractiveness of the target sector (biotechnology).
What are the main risks for HLXA?
The primary risk for HLXA is the failure to identify and complete a merger with a suitable biotechnology company within the specified timeframe, typically two years. If no merger occurs, the company will liquidate, and shareholders will receive their initial investment back, minus expenses. Other risks include overpaying for an acquisition target, shareholder disapproval of the merger, and poor performance of the acquired company post-merger. Regulatory changes and market volatility in the biotechnology sector also pose potential risks.
What are the key factors to evaluate for HLXA?
Helix Acquisition Corp. (HLXA) holds an AI score of 47/100 (low). Not financial advice.
How frequently does HLXA data refresh on this page?
HLXA prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven HLXA's recent stock price performance?
Helix Acquisition Corp. (HLXA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Experienced management team. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HLXA overvalued or undervalued right now?
Valuing Helix Acquisition Corp. (HLXA) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying HLXA?
Before investing in Helix Acquisition Corp. (HLXA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available data and may be subject to change.
- Investment in SPACs involves significant risk and is suitable for sophisticated investors only.